Mayzent Tablet, Film Coated
Product Images NDC 0078-1014

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Mayzent (NDC 0078-1014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Siponimod Structural Formula (Baf312 01)

Siponimod Structural Formula (Baf312 01)
FDA Label Image

Figure 1 Time To Confirmed Disability Progression Based On Edss (study 1) (Baf312 02)

Figure 1 Time To Confirmed Disability Progression Based On Edss (study 1) (Baf312 02)
This appears to be a graph or chart comparing results of a study between a drug called "Mayzent" and a placebo. The study involved 1,099 patients taking Mayzent and 546 taking a placebo. The graph shows the percentage of patients with confirmed EDSS progression over a period of time (12, 24, and 30 months). The study found that Mayzent showed a 21% reduction in relative risk compared to placebo, with a p-value of 0.013 and 95% confidence interval of 0.65 to 0.95.*
FDA Label Image

Figure 2 Time To Confirmed Disability Progression Based On Edss (study 1), Subgroup Analysis (Baf312 03)

Figure 2 Time To Confirmed Disability Progression Based On Edss (study 1), Subgroup Analysis (Baf312 03)
FDA Label Image

Novartis Logo (Baf312 04)

Novartis Logo (Baf312 04)
FDA Label Image

Principal Display Panel Ndc 0078-0986-15 Rx Only Mayzent® (siponimod) Tablets 2 mg 30 Tablets Dispense With Accompanying Medication Guide. Novartis (Baf312 05)

Principal Display Panel Ndc 0078-0986-15 Rx Only Mayzent® (siponimod) Tablets 2 mg 30 Tablets Dispense With Accompanying Medication Guide. Novartis (Baf312 05)
FDA Label Image

Principal Display Panel Ndc 0078-0979-50 Rx Only Mayzent® (siponimod) Tablets 0.25 mg 28 Tablets Dispense With Accompanying Medication Guide. Novartis (Baf312 06)

Principal Display Panel Ndc 0078-0979-50 Rx Only Mayzent® (siponimod) Tablets 0.25 mg 28 Tablets Dispense With Accompanying Medication Guide. Novartis (Baf312 06)
FDA Label Image

Baf312 07

Baf312 07

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.